Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1981 1
1995 2
1996 1
1998 2
1999 1
2000 2
2003 3
2004 3
2005 3
2006 1
2007 4
2008 2
2010 2
2011 4
2012 1
2013 2
2014 2
2015 2
2016 9
2017 20
2018 23
2019 20
2020 10
2021 3
2022 5
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 29262551

116 results

Results by year

Filters applied: . Clear all
Page 1
The combination of temozolomide-irinotecan regresses a doxorubicin-resistant patient-derived orthotopic xenograft (PDOX) nude-mouse model of recurrent Ewing's sarcoma with a FUS-ERG fusion and CDKN2A deletion: Direction for third-line patient therapy.
Miyake K, Murakami T, Kiyuna T, Igarashi K, Kawaguchi K, Miyake M, Li Y, Nelson SD, Dry SM, Bouvet M, Elliott IA, Russell TA, Singh AS, Eckardt MA, Hiroshima Y, Momiyama M, Matsuyama R, Chishima T, Endo I, Eilber FC, Hoffman RM. Miyake K, et al. Oncotarget. 2017 Sep 8;8(61):103129-103136. doi: 10.18632/oncotarget.20789. eCollection 2017 Nov 28. Oncotarget. 2017. PMID: 29262551 Free PMC article.
Effective molecular targeting of CDK4/6 and IGF-1R in a rare FUS-ERG fusion CDKN2A-deletion doxorubicin-resistant Ewing's sarcoma patient-derived orthotopic xenograft (PDOX) nude-mouse model.
Murakami T, Singh AS, Kiyuna T, Dry SM, Li Y, James AW, Igarashi K, Kawaguchi K, DeLong JC, Zhang Y, Hiroshima Y, Russell T, Eckardt MA, Yanagawa J, Federman N, Matsuyama R, Chishima T, Tanaka K, Bouvet M, Endo I, Eilber FC, Hoffman RM. Murakami T, et al. Oncotarget. 2016 Jul 26;7(30):47556-47564. doi: 10.18632/oncotarget.9879. Oncotarget. 2016. PMID: 27286459 Free PMC article.
Eribulin regresses a doxorubicin-resistant Ewing's sarcoma with a FUS-ERG fusion and CDKN2A-deletion in a patient-derived orthotopic xenograft (PDOX) nude mouse model.
Miyake K, Murakami T, Kiyuna T, Igarashi K, Kawaguchi K, Li Y, Singh AS, Dry SM, Eckardt MA, Hiroshima Y, Momiyama M, Matsuyama R, Chishima T, Endo I, Eilber FC, Hoffman RM. Miyake K, et al. J Cell Biochem. 2018 Jan;119(1):967-972. doi: 10.1002/jcb.26263. Epub 2017 Sep 12. J Cell Biochem. 2018. PMID: 28681998
Regorafenib regressed a doxorubicin-resistant Ewing's sarcoma in a patient-derived orthotopic xenograft (PDOX) nude mouse model.
Miyake K, Kiyuna T, Kawaguchi K, Higuchi T, Oshiro H, Zhang Z, Wangsiricharoen S, Razmjooei S, Li Y, Nelson SD, Murakami T, Hiroshima Y, Matsuyama R, Bouvet M, Chawla SP, Singh SR, Endo I, Hoffman RM. Miyake K, et al. Cancer Chemother Pharmacol. 2019 May;83(5):809-815. doi: 10.1007/s00280-019-03782-w. Epub 2019 Feb 13. Cancer Chemother Pharmacol. 2019. PMID: 30758647
High Efficacy of Pazopanib on an Undifferentiated Spindle-Cell Sarcoma Resistant to First-Line Therapy Is Identified With a Patient-Derived Orthotopic Xenograft (PDOX) Nude Mouse Model.
Igarashi K, Kawaguchi K, Murakami T, Kiyuna T, Miyake K, Singh AS, Nelson SD, Dry SM, Li Y, Yamamoto N, Hayashi K, Kimura H, Miwa S, Tsuchiya H, Eilber FC, Hoffman RM. Igarashi K, et al. J Cell Biochem. 2017 Sep;118(9):2739-2743. doi: 10.1002/jcb.25923. Epub 2017 Apr 25. J Cell Biochem. 2017. PMID: 28176365
Recombinant methioninase effectively targets a Ewing's sarcoma in a patient-derived orthotopic xenograft (PDOX) nude-mouse model.
Murakami T, Li S, Han Q, Tan Y, Kiyuna T, Igarashi K, Kawaguchi K, Hwang HK, Miyake K, Singh AS, Nelson SD, Dry SM, Li Y, Hiroshima Y, Lwin TM, DeLong JC, Chishima T, Tanaka K, Bouvet M, Endo I, Eilber FC, Hoffman RM. Murakami T, et al. Oncotarget. 2017 May 30;8(22):35630-35638. doi: 10.18632/oncotarget.15823. Oncotarget. 2017. PMID: 28404944 Free PMC article.
Temozolomide combined with irinotecan regresses a cisplatinum-resistant relapsed osteosarcoma in a patient-derived orthotopic xenograft (PDOX) precision-oncology mouse model.
Igarashi K, Kawaguchi K, Kiyuna T, Miyake K, Miyake M, Li Y, Nelson SD, Dry SM, Singh AS, Elliott IA, Russell TA, Eckardt MA, Yamamoto N, Hayashi K, Kimura H, Miwa S, Tsuchiya H, Eilber FC, Hoffman RM. Igarashi K, et al. Oncotarget. 2017 Dec 4;9(8):7774-7781. doi: 10.18632/oncotarget.22892. eCollection 2018 Jan 30. Oncotarget. 2017. PMID: 29487690 Free PMC article.
Growth of doxorubicin-resistant undifferentiated spindle-cell sarcoma PDOX is arrested by metabolic targeting with recombinant methioninase.
Igarashi K, Li S, Han Q, Tan Y, Kawaguchi K, Murakami T, Kiyuna T, Miyake K, Li Y, Nelson SD, Dry SM, Singh AS, Elliott IA, Russell TA, Eckardt MA, Yamamoto N, Hayashi K, Kimura H, Miwa S, Tsuchiya H, Eilber FC, Hoffman RM. Igarashi K, et al. J Cell Biochem. 2018 Apr;119(4):3537-3544. doi: 10.1002/jcb.26527. Epub 2018 Jan 2. J Cell Biochem. 2018. PMID: 29143983
Temozolomide regresses a doxorubicin-resistant undifferentiated spindle-cell sarcoma patient-derived orthotopic xenograft (PDOX): precision-oncology nude-mouse model matching the patient with effective therapy.
Igarashi K, Kawaguchi K, Kiyuna T, Miyake K, Miyake M, Li Y, Nelson SD, Dry SM, Singh AS, Elliott IA, Russell TA, Eckardt MA, Yamamoto N, Hayashi K, Kimura H, Miwa S, Tsuchiya H, Eilber FC, Hoffman RM. Igarashi K, et al. J Cell Biochem. 2018 Aug;119(8):6598-6603. doi: 10.1002/jcb.26792. Epub 2018 May 8. J Cell Biochem. 2018. PMID: 29737543 Clinical Trial.
116 results